Report Content
Chapter 1 Methodology & Scope
1.1 Market definitions
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Circulating tumor cells (CTC) industry 3600 synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Technology trends
2.1.4 Application trends
2.1.5 Product trends
2.1.6 Specimen trends
2.1.7 End-use trends
Chapter 3 Circulating Tumor Cells Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing incidence of cancer cases
3.2.1.2 Growing demand for early and rapid cancer diagnosis
3.2.1.3 Advancements in CTCs detection technologies
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost associated with CTC analysis and detection methods
3.2.2.2 Limited awareness and adoption
3.3 Growth potential analysis
3.3.1 By technology
3.3.2 By application
3.3.3 By product
3.3.4 By specimen
3.3.5 By end-use
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.5.1 U.S.
3.5.2 Europe
3.6 Technology landscape
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard, 2022
Chapter 5 Circulating Tumor Cells Market Size and Forecast, By Technology (USD Million)
5.1 Key trends, by technology
5.2 CTC detection and enrichment method
5.2.1 Immunocapture
5.2.1.1 Positive selection
5.2.1.2 Negative selection
5.2.2 Size-based separation
5.2.2.1 Membrane-based
5.2.2.2 Microfluidic-based
5.2.3 Density-based separation
5.2.4 Combined methods
5.3 CTC direct detection methods
5.3.1 SERS
5.3.2 Microscopy
5.3.3 Other direct detection methods
5.4 CTC analysis
Chapter 6 Circulating Tumor Cells Market Size and Forecast, By Application (USD Million)
6.1 Key trends, by application
6.2 Research
6.2.1 Cancer stem cell & tumorogenesis research
6.2.2 Drug / therapy development
6.3 Clinical
6.3.1 Screening and monitoring
6.3.2 Risk assessment
Chapter 7 Circulating Tumor Cells Market Size and Forecast, By Product (USD Million)
7.1 Key trends, by product
7.2 Devices or systems
7.3 Kits & assays
7.4 Consumables
Chapter 8 Circulating Tumor Cells Market Size and Forecast, By Specimen (USD Million)
8.1 Key trends, by specimen
8.2 Blood
8.3 Bone marrow
8.4 Other body fluids
Chapter 9 Circulating Tumor Cells Market Size and Forecast, By End-use (USD Million)
9.1 Key trends, by end-use
9.2 Research and academic institutes
9.3 Hospital and clinics
9.4 Diagnostic centers
Chapter 10 Circulating Tumor Cells Market Size and Forecast, By Region (USD Million)
10.1 Key trends, by region
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Rest of Latin America
10.6 MEA
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 Rest of MEA
Chapter 11 Company Profiles
11.1 Thermo Fisher Scientific Inc.
11.2 QIAGEN
11.3 Precision for Medicine
11.4 BIOCEPT, Inc.
11.5 Fluxion Biosciences, Inc.
11.6 Greiner Bio One International GmbH
11.7 Ikonisys Inc.
11.8 Miltenyi Biotec
11.9 IVDiagnostics
11.10 BioFluidica
11.11 Biolidics Limited
11.12 Creativ MicroTech, Inc.
11.13 LungLife AI, Inc.
11.14 Rarecells Diagnostics
11.15 ScreenCell
11.16 Sysmex Corporation
11.17 STEMCELL Technologies, Inc.
